CLARITIN RAPID DISSOLVE 10 MG
LORATADINE : 10 MG · DIN 02237734 · BAYER INC
Health Canada status: MARKETED
What is CLARITIN RAPID DISSOLVE?
CLARITIN RAPID DISSOLVE 10 MG contains LORATADINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02237734, held by BAYER INC, supplied as TABLET (ORALLY DISINTEGRATING) for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Dec-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02237734 |
|---|---|
| Brand name | CLARITIN RAPID DISSOLVE |
| Generic / active ingredient | LORATADINE : 10 MG |
| Manufacturer | BAYER INC |
| Strength | 10 MG |
| Dosage form | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R06AX13 LORATADINE |
| AHFS class | 04:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Dec-2014 |
| Original market date | 1998-05-05 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R06AX13 LORATADINE. 11 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 24 HOUR ALLERGY REMEDY | 10 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02280159 |
| ALLERGY REMEDY | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02375990 |
| ALLERTIN | 10 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02390388 |
| APO-LORATADINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02243880 |
| CLARITIN ALLERGY | 10 MG | TABLET | BAYER INC | MARKETED | DIN 00782696 |
| CLARITIN KIDS | 5 MG / 5 ML | SYRUP | BAYER INC | MARKETED | DIN 02241523 |
| CLARITIN KIDS RAPID DISSOLVE | 5 MG | TABLET (ORALLY DISINTEGRATING) | BAYER INC | MARKETED | DIN 02508761 |
| CLARITIN LIQUID CAPSULES | 10 MG | CAPSULE | BAYER INC | MARKETED | DIN 02404494 |
| LORATADINE | Strength | Tablet | APOTEX INC 150 Signet Drive Toronto Ontario Canada M9L 1T9 | MARKETED | DIN 02366444 |
| LORATADINE SOFT GEL CAPSULES | Strength | Capsule | APOTEX INC 150 Signet Drive Toronto Ontario Canada M9L 1T9 | MARKETED | DIN 02379481 |
Who else supplies LORATADINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LORATADINE appears in 1512 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.